Pfizer may so far have come up blank on the marketed vaccines it hoped to pick up through an AstraZeneca merger. But as it weighs any next M&A-related steps to expand its lineup, it's also embarking on a marketing initiative that could boost uptake of its current star, Prevnar 13.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.
Puerto Rico's drug production sector has had an eventful few years, with investments by Eli Lilly, Bristol-Myers Squibb and others being offset by cutbacks at Merck and Pfizer. Now the island can add another line to its list of positive events: Actavis is investing $48 million to revitalize assets it acquired in the takeover of Warner Chilcott.
Pfizer's run at AstraZeneca is officially at an end. No more will-they-or-won't-they speculation, for at least a few months. What we're hearing now is a story of pride, prejudice, poor timing and miscalculation. CEOs and company boards are people, too, after all.
Now that the deadline for any quick deal to acquire AstraZeneca has passed, about the only certainty to emerge from the wrecked takeover is that the last thing Pfizer can do now is go back to business as usual.
With the official deadline for any immediate takeover discussions looming on Monday, Pfizer picked up its ball and bat and headed for the lockers, officially calling an end to its odd quest to buy out AstraZeneca.
Four times Pfizer has made offers to buy AstraZeneca and four times, the U.K. company has said no. But the world's largest money-management firm hopes in this case no doesn't mean no. BlackRock--which owns 8% of AstraZeneca and 6.8% of Pfizer--is encouraging discussions between the two companies, according to Bloomberg, which cited anonymous sources.
In the latest EuroBiotech Report, while critics of Pfizer's attempt to buy AstraZeneca spent the week celebrating a major blow to the deal, an awkward question remains: Exactly what has been "saved" from Pfizer's clutches? And more.
It's not over yet. Another one of AstraZeneca's big investors appears to have joined the rebel group demanding that the board get to the bargaining table and see where it can take Pfizer's latest $120 billion offer. Citing sources, The Wall Street Journal reports that Legal & General, AstraZeneca's 6 th largest shareholder with a 3.5% stake in the company, wrote a letter to the board telling them they should engage in takeover talks.
So, Pfizer. What's Plan B? That's what investors are asking, now that CEO Ian Read's $117 billion bid for AstraZeneca hit a wall--and the promised trifecta of lower taxes, cost savings and promising drugs along with it.